AE Management for HER3-Targeted Tx
Current Considerations for Adverse Event Management With HER3-Directed Agents

Released: December 26, 2023

Rebecca S. Heist
Rebecca S. Heist, MD, MPH
Helena Yu
Helena Yu, MD

Activity

Progress
1
Course Completed

The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer.